Fiber Fermentation Study

University of Hohenheim21 enrolled

Overview

The aim of the study is to better understand the interplay between the intake of dietary fiber and intestinal bacteria, their metabolic activity and the effect on the intestinal barrier. The effect of two different dietary fiber supplements is tested (arabinoxylan \& ß-glucan versus inulin \& fructooligosaccharides) in a randomized crossover intervention trial including healthy volunteers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Intestinal Health

Interventions

Dietary fiber supplementationDIETARY_SUPPLEMENT

1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan) 2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 18 to 65 years * signed written informed consent * willingness not to change the dietary pattern in the course of the study Exclusion Criteria: * BMI below 18 or above 30 * acute or chronic gastrointestinal symptoms * neoplastic diseases * very strict diets, including raw foodists and frutarians * regular smoking (more than one box per day) * intake of antibiotics, immunosuppressants, or any intestinal therapeutics three months prior to study begin * supplementation of fibers three months prior to study begin * simultaneous participation in another clinical study * pregnancy / breastfeeding * relevant violations of the study protocol * intolerance to the fiber supplements (including wheat, oat, chicory) * occurrence of relevant diseases (individual decision by study physicians) * revocation of consent * placement in a clinic or similar facility based on an official or court order

Locations (1)

Institute of Nutritional Medicine, University of Hohenheim

Stuttgart, Germany

Outcomes

Primary Outcomes

Short-chain fatty acids (SCFAs)

SCFAs in native fecal samples

Time frame: Will be measured in approx. 4 weeks after study completion.

Secondary Outcomes

Gut microbiome composition

16S NGS sequencing

Time frame: Will be measured in approx. 6-8 weeks after study completion.

Gut barrier integrity

Lipopolysaccharide-binding protein (plasma) and zonulin (feces)

Time frame: Will be measured in approx. 4 weeks after study completion.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.